Annual Thierry Latran Foundation Grantees meeting 2018
SAID BUSINESS SCHOOL - Park End Street
Seminar Room A

Tuesday 19 June	**14h30 Welcome coffee**	
15h	**Wim Robberecht**	**Introduction**
15h15 - 15h45	Final presentation **N. Charlet-Berguerand**	**Model-ALS :** Novel animal models for Amyotrophic Lateral Sclerosis
15h45 – 16h15	Final presentation **G. Schiavo**	**ALS-GO!:** Deficits in axonal transport as a target for pharmacological intervention in ALS
16h15 - 16h45	Final presentation **E. Hornstein**	**miRNAgenetics:** Discovery of microRNA-related mutations in human ALS patient genomes
16h45– 17h05	Progress presentation **C. Lobsiger**	**PeriMAC:** Peripheral macrophages as a promising target to modulate ALS disease progression.
17h05 - 17h30	**Break**	
17h30 - 17h50	Progress presentation **D. Zytnicki**	**SPIN-ALS :** Can a spinal interneuronopathy contribute to motoneuron degeneration in ALS? An electrophysiological study on patients and mouse models of ALS.
17h50 - 18h10	Progress presentation **A. Chio/ P. Van Damme**	**INSPIRED:** EvaluatIon of disease oNset and disease Stage/severity in Patients with amyotrophIc lateRal sclErosis using fDg-pet imaging
18h10 – 18h30	Progress presentation **E. Horstein**	**Astrocyte secretome:** Investigating the role of exosomal RNA in C9orf72 astrocyte toxicity - moving towards gene therapy approaches
18h30 - 18h45	**V. de Broglie**	**The Thierry Latran Foundation**
19h	**COCKTAIL DINER**	**The Jam Factory, 4 Hollybush Row - 1 mn**

Wednesday 20 June		
9h - 9h20	Progress presentation **L. Van Den Bosch**	**ALS-HDAC6:** Preclinical testing of histone deacetylase 6 (HDAC6) inhibitors in a FUS mouse model of amyotrophic lateral sclerosis
9h20 - 9h35	Initiation presentation **M. Barkats / MG Biferi**	**GeneTherC9:** New gene therapy for C9ORF72-linked ALS-FTD
9h35 – 9h50	Initiation presentation **S. Corti / E. Hedlund**	**IS-ALS:** Modulating motor neuron vulnerability using the oculomotor restricted genes IGF-2 and SYT13 for ALS therapy
9h50 - 10h05	Initiation presentation **M. Otto**	**Aggregated-TDP43:** Detection of disease specific aggregates of TDP-43 in cerebrospinal fluid of ALS patients for disease specific diagnosis
10h05 - 10h30	**Break**	
10h30 - 10h45	Initiation presentation **K. Talbot**	**TDPBAC:** The contribution of cell autonomous and non-cell autonomous effects of mutant TDP-43 to disease onset and progression in a novel transgenic mouse model of ALS
10h45 - 11h	Initiation presentation **C. Verfaillie**	**ALS_OL :** Identification of defects in oligodendrocytes (OL) in familial and sporadic ALS and creation of an all human OL-neuron coculture system for screens of novel drugs that correct OL defects
11h00 - 11h15	Initiation presentation **J. Weishaupt**	**Mutimono:** A multicentric approach to monocyte alterations in ALS
11h15 - 11h30	**Wim Robberecht**	**Closing Remarks**